Skip Navigation Skip to content

Milestones

Shilpa Medicare has been on path of expansion ever since its inception in 1987. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. Currently we are one of the leaders in the Oncology market and offer a complete range of products in this segment spanning across APIs, formulations both in terms of R&D and manufacturing capabilities. Further to consolidation in field of oncology API and formulations, we are striving to put in our efforts in field of novel drug delivery systems and biotech products along with widening our focus to other therapy areas. Where we are today has been the result of our constant endeavors for more than two decades. We are proud to share our journey from being a small start-up to a well-recognized establishment …

Chronology of Events

×

2017

Total 9 DMFs were completed review by USFDA in support of various ANDAs.
Capecitbine ANDAs approved.
Three MAH applications approved in EU.

×

2016

First MAH application approved in EU.
First ANDA approved in USA.
Centralized Procedure for EU Marketing Authorization for ImatinibTablets granted.
API sites approved by USFDA.

×

2015

Started new R&D center for development of Nano Technology products in Bangalore.
Raichur both units got approval by US FDA.
Raichem Medicare (P) Ltd JV with ICE-Italy become operational.
Formulation Facility at Jadcherla Approved by USFDA.

×

2013

Shilpa Medicare Formulations facility (Manufacturing of Oral & Injectible (Onco Products) at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (Telangana) became fully operational.

×

2012

National Energy Conservation Award (Ist Prize in drugs & pharmaceuticals sector), by President of INDIA.

×

2011

Shilpa Medicare acquired a controlling stake in Hyderabad-based “Shilpa Therapeutics”

  • “State of Art R&D center established in Vizag and started its operations
  • “M/s Raichem Life Sciences Private Limited, a 100% subsidiary of Shilpa Medicare Ltd., merged with Shilpa Medicare Ltd.
  • “US operations started
×

2010

Shilpa Medicare successfully set up a 100% EOU project incurring a capital expenditure of nearly Rs. 1000 million.

  • RaichemLifesciencesPvt Ltd secured ISO 9001:2008 certification
  • ‘Best District Export Award’ given by FKCCI, Bangalore
  • “Star Export Excellence Award” given by VITC, Bangalore
×

2009

Shilpa Medicare listed on National Stock Exchange (NSE) on Dec 03, 2009.

  • Shilpa Medicare entered 50:50 joint venture with Industria Chimica SRL, Italy (ICE) and Prodotti Chini Alimetari SpA, Italy (PCA).
  • First DMF filed for Oncology API- Anastrozole.
×

2008

Govt. of India awarded 'Best Entrepreneur Award' to Mr. Vishnukant, MD-Shilpa Medicare.

  • Also - "Emerging India Runner Award” given by CNBC.
  • Also - "Star Export House" Status from Ministry of Commerce and Industry, Govt. of India.
×

2007

Shilpa Medicare acquired 100% stake in Loba Feinchemie GmbH, Austria

×

2004

First patent application filed

×

1995

Shilpa Medicare was listed on Bombay Stock Exchange on Jun 19, 1995

×

1993

Shilpa Medicare was converted into a Public Limited Company

×

1992

Antibacterial products manufacturing started for companies such as Bombay Drug House Pvt Ltd and GlaxoSmithKline Pharmaceuticals Ltd.

New production facilities inducted for the manufacture of Sodium methoxide by indigenously developed technology.

×

1989

Shilpa Medicare Ltd. started its first commercial production of Trimethoprim.

×

1987

Shilpa Medicare Ltd. established as Shilpa Antibiotics Ltd.